大突破！研究显示礼来“减肥神药”有助于缓解睡眠呼吸暂停症状_老虎社区_美港股上老虎

大突破！研究显示礼来“减肥神药”有助于缓解睡眠呼吸暂停症状

华尔街见闻04-17

分析认为，如果获得广泛的保险覆盖，礼来“减肥神药”可能惠及高达560万例睡眠呼吸障碍病例。本周三，减肥神药双雄之一的美国制药巨头礼来，再度公布了旗下GLP-1减肥药Zepbound的乐观试验结果——Zepbound不仅适用于肥胖症、糖尿病，还拥有改善睡眠呼吸暂停症状的潜力。Zepbound有望使阻塞性睡眠呼吸暂停患者症状改善63%公司周三发布的声明显示，在其“对抗OSA（SURMOUNT-OSA）...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2428317328?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/098638ea5d53d105ccae54cc482b7624","is_english":false,"pubTime":"2024-04-17 20:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2428317328","market":"hk","top_or_hot":-1,"title":"大突破！研究显示礼来“减肥神药”有助于缓解睡眠呼吸暂停症状","media":"华尔街见闻","content":"<div>\n<p>分析认为，如果获得广泛的保险覆盖，礼来“减肥神药”可能惠及高达560万例睡眠呼吸障碍病例。本周三，减肥神药双雄之一的美国制药巨头礼来，再度公布了旗下GLP-1减肥药Zepbound的乐观试验结果——Zepbound不仅适用于肥胖症、糖尿病，还拥有改善睡眠呼吸暂停症状的潜力。Zepbound有望使阻塞性睡眠呼吸暂停患者症状改善63%公司周三发布的声明显示，在其“对抗OSA（SURMOUNT-OSA）...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3712970\">网页链接</a>\n\n</div>\n","source":"wallstreetcn_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>大突破！研究显示礼来“减肥神药”有助于缓解睡眠呼吸暂停症状</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n大突破！研究显示礼来“减肥神药”有助于缓解睡眠呼吸暂停症状\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-17 20:50 北京时间&nbsp;&nbsp;&nbsp;<a href=https://wallstreetcn.com/articles/3712970><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>分析认为，如果获得广泛的保险覆盖，礼来“减肥神药”可能惠及高达560万例睡眠呼吸障碍病例。本周三，减肥神药双雄之一的美国制药巨头礼来，再度公布了旗下GLP-1减肥药Zepbound的乐观试验结果——Zepbound不仅适用于肥胖症、糖尿病，还拥有改善睡眠呼吸暂停症状的潜力。Zepbound有望使阻塞性睡眠呼吸暂停患者症状改善63%公司周三发布的声明显示，在其“对抗OSA（SURMOUNT-OSA）...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3712970\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4533","symbol_name":"AQR资本管理(全球第二大对冲基金)","start_time":0,"source_url":"https://wallstreetcn.com/articles/3712970","article_id":"2428317328","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/098638ea5d53d105ccae54cc482b7624"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3712970","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2428317328","pubTimestamp":1713358218,"columns":[],"sourceInfo":{"source_id":"wallstreetcn_hot_news","name":"华尔街见闻"},"weMediaInfo":null,"summary":"减肥神药再添一项适应症，礼来离万亿市值不远了？","collect":0,"end_time":0,"defaultTopTitle":"wallstreetcn.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","BK4007":"制药","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","BK4588":"碎股","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","BK4581":"高盛持仓","LU0882574055.USD":"富达全球健康医疗A ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0122379950.USD":"贝莱德世界健康科学A2","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LLY":"礼来","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0238689110.USD":"贝莱德环球动力股票基金","SG9999001176.USD":"United Global Healthcare Acc USD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD"},"translate_title":"Big break! Eli Lilly's \"weight loss drug\" helps ease sleep apnea symptoms, study shows","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/557f26ab93b3682cb0be93a7b421a0b2","symbols_score_info":{"LLY":1},"content_text":"分析认为，如果获得广泛的保险覆盖，礼来“减肥神药”可能惠及高达560万例睡眠呼吸障碍病例。本周三，减肥神药双雄之一的美国制药巨头礼来，再度公布了旗下GLP-1减肥药Zepbound的乐观试验结果——Zepbound不仅适用于肥胖症、糖尿病，还拥有改善睡眠呼吸暂停症状的潜力。Zepbound有望使阻塞性睡眠呼吸暂停患者症状改善63%公司周三发布的声明显示，在其“对抗OSA（SURMOUNT-OSA）” 三期实验中，Zepbound可使患有由肥胖引起的阻塞性睡眠呼吸暂停症患者夜间呼吸减慢或停止的次数从基线水平下降高达63%，超出了投行杰富瑞、摩根士丹利等预期的50%降幅。实验显示，服用替尔泊肽（Tirzepatide，减肥药Zepbound和Mounjaro中的活性成分）后，阻塞性睡眠呼吸暂停患者的症状改善了55%，而接受安慰剂的患者症状改善了5%；而如果将药物与持续气道正压（CPAP）治疗设备联合使用，则可以让患者症状改善62.8%。此外，参与为期52周药物试验的患者体重也减轻了约20%。礼来计划于6月在美国糖尿病协会大会上分享完整的试验结果，并将于今年年中向美国食品药品监督管理局（FDA）和其他全球监管机构提交这些数据，以寻求批准Zepbound用于治疗睡眠呼吸暂停症。如果获批，Zepbound将有助于更多患者通过保险获得减重治疗。目前，美国联邦医保等医疗保险计划尚未承保诸如Zepbound的减重药物。礼来，向万亿美元市值进发？根据2019年发表在《柳叶刀》杂志上的一项研究，全球大约有10亿人受到睡眠呼吸暂停症的影响。睡眠呼吸暂停症患者通常需要使用呼吸机或植入物来保持呼吸道通畅。这些设备价格不菲，单件设备费用从数百到数千美元不等。根据GoodRx的数据，年度维护、服务和更换零件的平均费用在330至900美元之间。据分析公司Airfinity估计，减重有助于缓解睡眠呼吸暂停症，该症影响着2300多万名美国肥胖成年人。如果获得广泛的保险覆盖，到2030年，Zepbound可能防止高达560万例睡眠呼吸障碍病例。Airfinity也认为，如果Zepbound获批用于治疗睡眠呼吸暂停症，这也将影响到瑞思迈公司和Inspire Medical Systems等呼吸设备制造商。根据Airfinity的分析，在未来几年内，减重药物可能会使呼吸设备市场萎缩逾11%。华尔街见闻此前文章提到，摩根士丹利认为，替尔泊肽在睡眠呼吸暂停症上的乐观试验结果，有望产生减重领域之外的“溢出效应”，并推动医保覆盖，继续拓宽护城河。Carnegie Investment Counsel投资组合经理Shams Afzal也相信，从治疗心力衰竭到睡眠呼吸暂停，礼来的减肥疗法有望开拓新的市场，这可能将成为推动礼来向万亿美元迈进：礼来已真正成为生物制药领域的独角兽，未来将触及一万亿美元。截至发稿，礼来盘前涨超2%。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}